Fresenius Medical Care AG & Co. KGaA (FMS) to Post Quarterly Earnings on Tuesday

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $0.6150 per share and revenue of $5.4842 billion for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.05 earnings per share (EPS) for the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%.The business had revenue of $5.34 billion for the quarter. On average, analysts expect Fresenius Medical Care AG & Co. KGaA to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Fresenius Medical Care AG & Co. KGaA Stock Performance

Shares of FMS opened at $24.90 on Tuesday. The business’s fifty day simple moving average is $23.07 and its two-hundred day simple moving average is $22.88. The company has a current ratio of 1.20, a quick ratio of 0.86 and a debt-to-equity ratio of 0.40. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $20.02 and a 12 month high of $27.64. The company has a market cap of $13.38 billion, a price-to-earnings ratio of 13.11, a P/E/G ratio of 4.37 and a beta of 0.78.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The firm also recently declared an annual dividend, which was paid on Monday, June 8th. Stockholders of record on Friday, May 22nd were paid a $0.8716 dividend. This is an increase from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. This represents a dividend yield of 402.0%. The ex-dividend date was Friday, May 22nd. Fresenius Medical Care AG & Co. KGaA’s dividend payout ratio (DPR) is presently 32.11%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on FMS shares. Jefferies Financial Group raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a report on Friday, May 8th. Sanford C. Bernstein initiated coverage on Fresenius Medical Care AG & Co. KGaA in a report on Thursday, July 16th. They issued a “market perform” rating for the company. Wall Street Zen lowered Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday, July 17th. Finally, Weiss Ratings downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Hold rating and five have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $23.95.

Hedge Funds Weigh In On Fresenius Medical Care AG & Co. KGaA

Several hedge funds and other institutional investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after buying an additional 1,103 shares during the last quarter. Arax Advisory Partners increased its position in Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock valued at $38,000 after acquiring an additional 885 shares during the last quarter. Kestra Advisory Services LLC purchased a new stake in Fresenius Medical Care AG & Co. KGaA during the fourth quarter valued at $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter valued at about $58,000. Finally, Group One Trading LLC bought a new position in Fresenius Medical Care AG & Co. KGaA in the third quarter valued at about $74,000. 8.37% of the stock is owned by institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.